European Commission Approves Lilly's Ramucirumab (CYRAMZA®) for Advanced Non-Small Cell Lung Cancer (NSCLC) and Metastat

About Lilly Oncology For more than fifty years, Lilly has been dedicated to delivering life-changing medicines and support to people living with cancer and those who care for them. Lilly is determined to build on this heritage and continue making life better for all those affected by cancer around the world.

About Eli Lilly and CompanyLilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com [http://www.lilly.com/] and newsroom.lilly.com/social-channels [http://newsroom.lilly.com/social-channels].

CYRAMZA() is a trademark owned by or licensed to Eli Lilly and Company, its subsidiaries, or affiliates.

Lilly Forward-Looking Statement This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about ramucirumab (CYRAMZA()) as a potential treatment for patients with advanced non-small cell lung and metastatic colorectal cancers and reflects Lilly's current belief. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of development and commercialisation. Among other things, there can be no guarantee that future study results will be consistent with the results to date or that ramucirumab will achieve its primary study endpoints or receive regulatory approvals. For further discussion of these and other risks and uncertainties, see Lilly's most recent Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.

(1) Garon EB, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet. 2014;384:665-73.

(2) Josep Tabernero, et al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet. Published online April 13, 2015.

(3) Globocan: Lung: Estimated Cancer Incidence, Mortality and Prevalence Worldwide, 2012. http://globocan.iarc.fr/Pages/fact_sheet... Accessed: January 14, 2016.

(4) American Cancer Society. What is non-small cell lung cancer? http://www.cancer.org/cancer/lungcancer-non-smallcell/detail.... Updated March 4, 2015. Accessed: January 14, 2016.

(5) Carrato A, et al. Clinical management patterns and treatment outcomes in patients with non-small cell lung cancer (NSCLC) across Europe: EPICLIN-Lung study. Curr Med Res Opin. 2014;30:447-461.

(6) Globocan: Colorectal: Estimated Cancer Incidence, Mortality and Prevalence Worldwide, 2012. http://globocan.iarc.fr/Pages/fact_sheet... Accessed: January 14, 2016.

(7) Globocan: Estimated Incidence, Mortality and 5-Year Prevalence: Both Sexes Worldwide, 2012. http://globocan.iarc.fr/Pages/fact_sheet... Accessed: January 14, 2016.

(8) Globocan: Estimated Cancer Incidence, Mortality and Prevalence: Both Sexes European Union, 2012. http://globocan.iarc.fr/Pages/fact_sheet... Accessed: January 14, 2016.

(9) Tanigawa N, Amaya H, Matsumura M, et al. Correlation between expression of vascular endothelial growth factor and tumor vascularity, and patient outcome in human gastric carcinoma. J Clin Oncol. 1997;15:826-32.

(10) Yoshikawa T, Tsuburaya A, Kobayashi O, et al. Plasma concentrations of VEGF and bFGF in patients with gastric carcinoma. Cancer Lett. 2000;153:7-12.

(11) Seto T, Higashiyama M, Funai H, Imamura F, Uematsu K, Seki N, Eguchi K, Yamanaka T, Ichinose Y. Prognostic value of expression of vascular endothelial growth factor and its flt-1 and KDR receptors in stage I non-small-cell lung cancer. Lung Cancer. 2006;53(1):91-96.

(12) Bruns CJ, Liu W, Davis DW, et al. Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases. Cancer. 2000;89:488-99.

Refer to: Tracy Henrikson; tracy.henrikson@lilly.com; +1 (609)

240-3902 (Lilly Oncology)

Mariann Caprino; m.caprino@togorun.com; +1 (917) 242-1087

(TogoRun)

Logo -- http://photos.prnewswire.com/prnh/200312... [http://photos.prnewswire.com/prnh/200312...]

Web site: http://www.lilly.com/